{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:49:02Z","timestamp":1793879342978,"version":"4.7.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250099-4\"><jats:title>Importance<\/jats:title><jats:p>Gram-negative bloodstream infections are a common cause of hospitalization. A 2-week duration of antibiotic therapy has been commonly used, but shorter durations may have similar outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-5\"><jats:title>Objectives<\/jats:title><jats:p>To assess whether 7 days of antibiotic therapy was noninferior to 14 days.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-6\"><jats:title>Data Sources<\/jats:title><jats:p>Starting with a 2022 individual patient data meta-analysis, PubMed, Cochrane Central Register of Controlled Trials, and Web of Science were searched to identify additional eligible randomized clinical trials (RCTs) conducted from May 1, 2022, until November 30, 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-7\"><jats:title>Study Selection<\/jats:title><jats:p>RCTs involving primarily adults who were hospitalized at the time of Gram-negative bloodstream infection and were allocated to 7 or 14 days of antibiotic therapy. Studies were independently reviewed by 2 investigators.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>PRISMA guidelines were followed. Data were extracted by 2 investigators. Any unpublished data were obtained directly from study authors. Risk of bias and certainty of the evidence were assessed in duplicate using the Cochrane Risk of Bias Tool, version 2, and the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled by separate random-effects meta-analyses for the intention-to-treat (ITT) and per-protocol (PP) populations. A noninformative prior probability was used for the effect, and an evidence-based weakly informative prior probability was used for heterogeneity. Risk ratios (RRs), 95% credible intervals (CrIs), and probability of noninferiority were calculated using a prespecified upper bound of 1.25 or less.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Ninety-day all-cause mortality.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-10\"><jats:title>Results<\/jats:title><jats:p>Four eligible RCTs contributed 3729 patients in the ITT population (1912 women [51.3%]; median age range, 67-79 years) and 3126 in the PP population. In the ITT analysis, within 90 days, 226 patients (12.0%) receiving 7 days of antibiotics died compared with 253 (13.7%) receiving 14 days, corresponding to an RR for 90-day mortality of 0.91 (95% CrI, 0.69-1.22) and a 97.8% probability of noninferiority. In the PP analysis, the RR was 0.93 (95% CrI, 0.68-1.32), corresponding to a 95.1% probability of noninferiority.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250099-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this systematic review and meta-analysis of patients with Gram-negative bloodstream infections and adequate source control, 7 days of antibiotic therapy had a high probability of being noninferior to 14 days. These findings support a shorter duration of antibiotic therapy for appropriately selected patients like those in the included RCTs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.1421","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:49:44Z","timestamp":1742575784000},"page":"e251421","source":"Crossref","is-referenced-by-count":31,"title":["Seven vs Fourteen Days of Antibiotics for Gram-Negative Bloodstream Infection"],"prefix":"10.1001","volume":"8","author":[{"given":"Todd C.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Prosty","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fralick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sinai Health and University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molina","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Microbiology and Parasitology, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), Virgen del Roc\u00edo University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Rambam Health Care Campus, Technion\u2013Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Sunnybrook Health Sciences Center, University of Toronto, Institute of Health Policy, Management, and Evaluation, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgar","family":"Rishu","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"von Dach","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Sheba Medical Center, Faculty of Medical & Health Sciences, Tel Aviv University, Ramat-Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"1","key":"zoi250099r1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac706","article-title":"Can the future of ID escape the inertial dogma of its past? the exemplars of shorter is better and oral is the new IV.","volume":"10","author":"Davar","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"zoi250099r2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ijantimicag.2011.07.016","article-title":"Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists.","volume":"38","author":"Daneman","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"zoi250099r3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven- versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial.","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"zoi250099r4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a noninferiority randomized controlled trial.","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"21","key":"zoi250099r5","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated Gram-negative bacteremia: a randomized clinical trial.","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"zoi250099r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101750","article-title":"Duration of antibiotic treatment for Gram-negative bacteremia\u2014systematic review and individual participant data (IPD) meta-analysis.","volume":"55","author":"Turjeman","year":"2023","journal-title":"EClinicalMedicine"},{"key":"zoi250099r7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections.","author":"BALANCE Investigators","journal-title":"N Engl J Med"},{"key":"zoi250099r8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jclinepi.2020.05.034","article-title":"Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions.","volume":"127","author":"Acuna","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"zoi250099r11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"zoi250099r12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"7650","key":"zoi250099r13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"zoi250099r15","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R package.","author":"R\u00f6ver","journal-title":"J Stat Softw"},{"issue":"6","key":"zoi250099r16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in bayesian meta-analysis.","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"issue":"4","key":"zoi250099r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044480","article-title":"Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics.","volume":"11","author":"Pong","year":"2021","journal-title":"BMJ Open"},{"issue":"4","key":"zoi250099r18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cmi.2021.10.022","article-title":"Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis.","volume":"28","author":"Curran","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"zoi250099r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277333","article-title":"Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial).","volume":"17","author":"Molina","year":"2022","journal-title":"PLoS One"},{"key":"zoi250099r9","unstructured":"Lee? TC. Duration of therapy for uncomplicated Gram-negative bacteremia. OSF. September 26, 2024. Accessed October 2, 2024. https:\/\/osf.io\/c6a8z"},{"key":"zoi250099r10","unstructured":"Higgins? JPT, Eldridge? S, Li? T, eds. Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4. Cochrane; 2023. Updated August 2023. http:\/\/www.training.cochrane.org\/handbook"},{"key":"zoi250099r14","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University and Evidence Prime; 2025. Accessed October 21, 2024. https:\/\/www.gradepro.org"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831846\/lee_2025_oi_250099_1744988260.78289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:00:27Z","timestamp":1745506827000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831846"}},"subtitle":["A Systematic Review and Noninferiority Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1421","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}